Reuben Harris, PhD of University of Minnesota, Minneapolis, MN talks about APOBEC-3B as a candidate biomarker for response to therapy. Tumors expressing higher levels of APOBEC-3B and APOBEC-3H are more likely to have a higher overall mutation rate and evolvability. Dr Harris points out that targeted therapies could become undermined by resistance mutations, especially in a tumor that is mutating at a high rate. Recorded at the 2016 National Cancer Research Institute (NCRI) Conference in Liverpool, UK.
Get great new content delivered to your inboxSign up
By choosing to continue, you are confirming that you are a healthcare professional
Please enter your details if you would like to receive the latest oncology news and updates